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Abstract
The Notch ligand, Dll4, is essential for angiogenesis during embryonic vascular development and is involved in tumour angiogenesis.
Several recent publications demonstrated that blockade of Dll4 signalling inhibits tumour growth, suggesting that it may constitute a good
candidate for anti-cancer therapy. In order to understand the role of Dll4 at the cellular level, we performed an analysis of Dll4-regulated genes
in HUVECs. The genes identified included several angiogenic signalling pathways, such as VEGF, FGF and HGF. In particular we identified
downregulation (VEGFR2, placenta growth factor PlGF) of VEGF pathway components resulting in the overall effect of limiting the response
of HUVEC to VEGF. However extensive upregulation of VEGFR1 was observed allowing continued response to its ligand PlGF but the
soluble form of the VEGFR1, sVEGFR1 was also upregulated. PlGF enhanced tubulogenesis of HUVEC suggesting that downregulation of
PlGF and upregulation of VEGFR1 including sVEGFR1 are important mechanisms by which Dll4 attenuates PlGF and VEGF signalling. Dll4-
stimulated HUVECs had impaired ERK activation in response to VEGF and HGF indicating that Dll4 signalling negatively regulates these
pathways. Dll4 expression reduced vessel sprout length in a 3D tubulogenesis assay confirming that Dll4 signalling inhibits angiogenesis.
Altogether, our data suggest that Dll4 expression acts as a switch from the proliferative phase of angiogenesis to the maturation and
stabilisation phase by blocking endothelial cell proliferation and allowing induction of a more mature, differentiated phenotype. The regulation
of sVEGFR1 provides a novel mechanism for Dll4 signalling to regulate cells at distance, not just in adjacent cells.
© 2007 Elsevier Inc. All rights reserved.
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Introduction
Notch signalling has recently been implicated in vascular
development and homeostasis since genes encoding compo-
nents of Notch signalling are mutated in two human diseases
(Alagille Syndrome and CADASIL (Cerebral Autosomal
Dominant Arteriopathy with Subcortical Infarcts and Leukoen-
cephalopathy)) which exhibit vascular defects (Karsan, 2005;
Shawber and Kitajewski, 2004). Furthermore, many Notch
receptors and ligands are expressed in cells of the vasculature
(Iso et al., 2003a; Villa et al., 2001). Finally studies of trans-
genic mice have revealed an essential early role for Notch
signalling in angiogenesis (Iso et al., 2003a).
Notch signalling is an evolutionarily conserved intercellular
signalling pathway mediated by membrane-tethered receptor–
ligand interactions between adjacent cells (Artavanis-Tsakonas
et al., 1999; Lai, 2004). Receptor–ligand binding induces
sequential cleavages of the Notch receptor, the last of which is
performed by the γ-secretase complex, releasing the Notch
intracellular domain (NICD) which translocates to the nucleus
(Artavanis-Tsakonas et al., 1999; Lai, 2004). In the nucleus
NICD typically interacts with RBP-Jκ (recombination signal
binding protein Jκ) leading to the transcription of Notch target
genes such as members of the Hes and Hey families of
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transcriptional repressors (Iso et al., 2003b). In mammals there
are four Notch receptors (Notch1–4) and 5 Notch ligands: two
serrate-like ligands named Jagged1 and Jagged2 and three
delta-like ligands (Dll) named Dll1, 3, 4.
We and others have shown that Dll4 is expressed specifically
at sites of vascular development and angiogenesis and is con-
fined to arterial ECs (Benedito and Duarte, 2005; Claxton and
Fruttiger, 2004; Mailhos et al., 2001; Shutter et al., 2000). Dll4
expression is particularly critical for angiogenesis as haplo-
insufficiency of Dll4 leads to embryonic lethality in mice due to
vascular defects (Duarte et al., 2004; Gale et al., 2004; Krebs et
al., 2004) demonstrating the essential role of Dll4 in angio-
genesis during development.
Thus Dll4 expression is essential for normal angiogenesis
during development but Dll4 expression in adults is confined to
areas of physiological angiogenesis such as in the ovary around
developing follicles and areas of pathological angiogenesis such
as tumour vasculature (Mailhos et al., 2001). Recent evidence
suggests that Dll4 expression is upregulated in tumour
endothelium and that this correlates with tumour vessel
maturation and remodeling (Hainaud et al., 2006; Patel et al.,
2006). In addition Dll4 expression is induced by hypoxia, a
common feature of tumour development known to induce
angiogenesis (Mailhos et al., 2001) making Dll4 an attractive
anti-tumour target. Indeed recent papers have demonstrated that
blockade of Dll4 signalling promotes non-productive angiogen-
esis thus inhibiting tumour growth (Noguera-Troise et al., 2006;
Ridgway et al., 2006) though the mechanistic basis for this
remains unclear. In the present study we performed a cDNA
microarray screen to identify Dll4 regulated genes in order to
understand the function of Dll4 signalling in physiological and
pathological angiogenesis.
Materials and methods
Cell culture, cells and reagents
HUVECs were isolated from fresh human umbilical cords by infusion with
0.2% collagenase. Single donor HUVECs were used between passages 3 and 7
and were cultured in M199 media supplemented with 20% fetal calf serum
(FCS: Sigma-Aldrich, St. Louis, MO), 12 mM L-glutamine, 50 mg/L ECGS
(endothelial cell growth supplement; BD Biosciences Bedford MA, USA),
10 units/mL heparin (Sigma) and an antimycotic/antibiotic (Gibco). The
Phoenix amphotropic viral packaging cell line (gift from Garry Nolan) was
cultured in DMEM supplemented with 10% FCS, 12 mM L-glutamine and
penicillin/streptomycin. Recombinant human Dll4 extracellular domain (rDll4)
was purchased from R&D Systems (Minneapolis, USA). The γ-secretase
inhibitor DAPT (Calbiochem) was dissolved in DMSO (Sigma) and used at a
final concentration of 2 μM.
Retroviral packaging and infection
The retroviral vector and full length human Dll4 construct have been pre-
viously described (Williams et al., 2006). Low passage, 50% confluent HUVECs
were infected using 0.4-μm filtered virus containing supernatant supplemented
with 4 ng/mL polybrene. After 5 h at 37 °C an equal volume of normal HUVEC
culture media was added. Infection efficiencies were from 60% to 90%.
Microarray analysis
Microarray analysis was performed in triplicate and each replicate used
HUVECs from a different donor. Total RNAwas extracted from HUVECs using
TRI-reagent (Sigma) followed by DNase I treatment (DNase-free; Ambion)
according to the manufacturer's instructions. First and second strand cDNA
synthesis was performed using Superscript dscDNA Synthesis Kit (Invitrogen)
and 10 μg of total RNA.Clean-up of double stranded cDNAwas carried out using
Phase Lock Gels, 2 mL light (Eppendorf), followed by synthesis of labeled
cRNA with the BioArray High Yield RNA Transcript Labeling Kit (ENZO,
Affymetrix). Purification of cRNA and quantification was done with RNeasy
Mini Kit (Qiagen), followed by cRNA Fragmentation using 30 μg cRNA and
Fragmentation Buffer (200 mM Tris-acetate pH 8.1, 500 mMMKOAc, 150 mM
MgOAc). Hybridisation Cocktail for humanHG-U133AAffymetrix GeneChip®
utilised the Gene Chip Eurkaryotic Hybridisation Control Kit (ENZO,
Affymetrix) and hybridisation, washing, staining, and scanning of the chip was
performed according to the manufacturer's instructions. Data was labeled as
MIAME compliant. Raw signal files were background corrected and normalised
using the gcrma modification of the rma normalisation procedure (Irizarry et al.,
2003) available from the Bioconductor project (www.bioconductor.org) for the R
statistical language. Log2 ratios of Dll4 signal to control signal were generated
for each probeset. A list was generated that contained those probesets for which
an average absolute fold change of at least 1.5 was observed between Dll4 and
control samples. Where a gene was represented by more than one probeset the
average signal value was used. This list was used to generate a list of statistically
significant (P≤0.01) probesets with the eBayes approach (Smyth, 2004) as
implemented in the limma package (Smyth and Speed, 2003) of BioConductor.
Visualisation of this gene list was performed using the hierarchical clustering
algorithm with euclidean distance and single linkage. Enrichment analysis was
conducted using the DAVID algorithm and significance of enrichment is
measured using the Fisher's Exact Test for each GO term relative to the
background of the Affymetrix HG-U133A chip.
Quantitative real time PCR (Q-PCR)
Reverse transcription was performed using 1 μg total DNase 1-treated RNA
and the High Capacity cDNA Archive Kit (Applied Biosystems). The resulting
cDNA was used for Q-PCR using the Exiqon system (Roche, Basel, Switzer-
land). Briefly Q-PCR reactions were set up in triplicate using the Corbett
Research Roto Gene RG-3000 robot (Corbett, Sydney, Australia). Each 25 μl
reaction contained the equivalent of 25 ng reverse transcribed cDNA, 0.4 μM of
each oligonucleotide, 12.5 μl of 2× Absolute QPCR master mix (AbGene,
Epsom, UK) and 0.25 μl of the appropriate Exiqon probe. GAPDH or Flo2 were
used as reference genes to normalise results. The cycling conditions used were:
95 °C for 10 min followed by 40 cycles of 95 °C for 15 s and 60 °C for 60 s. The
relative quantitation was performed as previously described (Patel et al., 2005).
The differences between Q-PCR experimental groups were analyzed using one
sample Student's t test and pb0.05 was considered significant.
Oligonucleotides
Gene Forward 5′–3′ Reverse 5′–3′
GAPDH AGCCACATCGCTCAGACAC GCCCAATACGACCAAATCC
Flo2 CTCAGCTTCACCATCAAGGAC TCAGCATCTCTCTGCACCAC
Sulfatase1 CCAATGCTTCCCAACACATA GCATTGGTCCTGTGTACTGC
Elastin CACTGGGGTATCCCATCAAG GTGGTGTAGGGCAGTCCATAG
PCDH12 GGAGGAGCTCACTGTGGATT CTGATGCAGCAAGGACAGC
INHBA CTCGGAGATCATCACGTTTG CCTTGGAAATCTCGAAGTGC
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Gene Forward 5′–3′ Reverse 5′–3′
SDC1 CCAGTCAGCTCCCAGCAG CCCCGAGGTTTCAAAGGT
CDH11 ACCAAAGTTTCCGCAGAGC TGGATCTTTAGCTTTCACTCTTCC
STAT1 AAAGTATTACTCCAGGCCAAAGG CCAGTTCCTTTAGGGCCATC
Biglycan CAGCCCGCCAACTAGTCA GGCCAGCAGAGACACGAG
SNAI2 GAACAAAACACAGGAGAATGTATTAAA GCCAGGAATGTTCAAAGCTAA
VCAM1 TGGACATAAGAAACTGGAAAAGG GATTTCTGGATCTCTAGGGAATGA
RASSF2 TGAAGGCCAGAATTTACAGCTC CCCTCCACAATGAACTCGTC
FBLN5 CTGCCCTCCAGGCTACATC CCTGTGCTCACATTCGTTGA
NRP2 GGACCCCCAACTTGGATT ATGGTTAAAAAGCGCAGGTC
SEMA5A ATGGAGATCGCCAACTGTTC TAGTGCTGCAGGGAGACCA
VEGFR1 CAGCATACCTCACTGTTCAAGG CCACACAGGTGCATGTTAGAG
MET ACCAAAATGGCTACACACTGG CATTCAATGGGATCTTCGTGA
Hey2 CCAGCAGTGCATCAGTATGTC CAGGCACTTACGAAACACGA
PlGF GGCTGTTCCCTTGCTTCC CAGACAAGGCCCACTGCT
Jagged1 TGGGCTTTGAGTGTGAGTGT CCCCGTGGGAACAGTTATTA
Notch3 CAATGCTGTGGATGAGCTTG AAGTGGCTTCCACGTTGTTC
RGC32 CAGACTCTACCCCAGCTCTTCT GCTCTTTTGTGTCTCCTAATTTAGCTT
Dll4 CCCTGGCAATGTACTTGTGAT TGGTGGGTGCAGTAGTTGAG
rDll4-coated tissue culture plates
Tissue culture plates were coated with 0.2% gelatine (w/v) in PBS
containing 1 μg/mL rDll4 or BSA as a control (Williams et al., 2006) and
incubated at 4 °C for 24 h before use. Plates were warmed to 37 °C and the
coating solution aspirated prior to seeding 2×105 HUVECs per well in 6-well
plates. RNA, protein (as per serum stimulation of HUVECs below) or
conditioned media were harvested 48 h later.
γ-Secretase treatment
2×105 HUVECs were seeded in the presence of 2 μMDAPTor an equivalent
amount of DMSO vehicle. The media containing DAPT or DMSO control was
replaced after 24 h (except when used for ELISA). RNA, protein (as per
stimulation of HUVECs below) or conditioned media was harvested after 48 h.
Western blotting
Proteins were separated by SDS-PAGE using standard techniques.
Antibodies were purchased from the following companies: Notch1IC, MET,
STAT1, phospho-ERK and total ERK antibodies (Cell Signalling), Jagged1,
Notch3, VEGFR2, Snai2 (Santa Cruz), β-tubulin, β-actin, VEGFR1 antibodies
(Sigma). The anti-Hes1 antibody was a gift from Tetsuo Sudo, Toray Industries,
Japan. Anti-mouse and anti-rabbit HRP conjugated secondary antibodies were
from DAKO while anti-goat HRP was from Perbio.
VEGF165, HGF and PlGF stimulation of HUVECs
2×105 HUVECs per well were seeded into BSA control or rDll4-coated 6-
well plates. After 43 h the media was replaced with starvation media (DMEM
with 0.5% FCS). 5 h later the media was replaced with starvation media
(unstimulated) or starvation media supplemented with 20 ng/mL VEGF165 or
HGF for 2 or 10 min or 10 ng/mL PlGF for 2.5, 5 and 10 min. Cells were
lysed in RIPA buffer (Sigma) supplemented with Complete protease inhibitor
cocktail (Roche) and phosphatase inhibitor cocktails I and II (Sigma).
Following centrifugation (13,000 rpm, 5 min at 4 °C) the supernatant was
collected. Equal amounts of protein were separated by SDS-PAGE as
described above.
In vitro 3D-tubulogenesis fibrin gel bead assay
The fibrin gel bead assay was previously described (Nakatsu et al., 2003).
HUVECs were infected with retrovirus encoding for GFP (empty vector control)
or full-length Dll4 as described above and subsequently placed in the fibrin gel
bead assay. To investigate the effect of PlGF, HUVEC were placed in the fibrin
gel bead assay and treated 2 days later with vehicle- or 10 ng/mL or 50 ng/mL
PlGF-containing EGM-2, replacing the media every other day for a total of 5
treatments. A Zeiss Axiovert S100 microscope using 10x and 20x objectives
attached to a Hamamatsu C4742-95 camera was used to capture images. Image
acquisition software used was OpenLab 3.5 and Image J software (NIH) was
used for the analysis of sprout length (Nakatsu et al., 2003).
Soluble VEGFR1 ELISA
2×105 HUVEC were seeded on BSA or rDll4-coated plates as described
above except that EGM-2 media was used. ELISA for human sVEGFR1 (R&D
Systems) was performed according to the manufacturer's instructions using the
conditioned media (diluted 1 in 10 in EGM-2 media) from HUVECs cultured
on BSA- or rDll4-coated plates in the presence of DMSO or DAPT for 48 h.
Total ng of sVEGFR1 were normalised to the amount of cellular protein in mg
to account for differences in proliferation.
Results
Exogenous Dll4 enhances Notch signalling in HUVECs
HUVECs were chosen for this study because of their
capacity to express low levels of Dll4 mRNA as detected by RT-
PCR (Patel et al., 2005) and to induce Dll4 expression following
hypoxia and VEGF stimulation (Hainaud et al., 2006; Liu et al.,
2003; Mailhos et al., 2001; Patel et al., 2005). Transduction of
HUVECs with Dll4-encoding retrovirus increased Dll4 expres-
sion at the mRNA and protein levels as previously reported
(Williams et al., 2006).
Identification of Dll4 target genes by microarray analysis
In order to identify genes and processes regulated by Dll4
signalling that are responsible for its role in regulating
angiogenesis we performed cDNA microarray analysis in
triplicate comparing Dll4-retrovirally-infected HUVECs to
control empty vector-infected HUVECs. Analysis of the
microarray data revealed 104 candidate genes that were
statistically significantly up or downregulated by an average
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of more than 1.5 fold in Dll4-infected HUVECs compared to
control-infected HUVECs (pb0.01; Fig. 1 and Supplementary
Table 1). Table 1 shows that Dll4 regulated a wide variety of
genes including components of cell signalling pathways
important for angiogenesis such as the VEGF, FGF and
hepatocyte growth factor (HGF) signalling pathways. Indeed
the list of 104 genes is significantly enriched for GO terms
of angiogenesis (p=0.00012), and angiogenesis-associated
processes, including proliferation (p=0.018) and cell adhe-
sion (p=0.029). The gene functional classification algorithm
within DAVID produced a cluster of angiogenesis related
GO terms that had a geometric mean significance of enrich-
ment of (p=0.0012). Dll4 upregulated more genes than it
downregulated.
Validation of candidate Dll4 target genes by Q-PCR
Using Q-PCR we analysed the mRNA levels of candidate
genes in Dll4-infected HUVECs compared to empty vector-
infected HUVECs for a panel of 14 genes up-regulated in the
microarray analysis and 5 genes that were down regulated.
Genes were chosen from the list of 104 genes and also a longer
list of genes regulated by Dll4 by 1.5 fold or more
(Supplementary Table 2). Q-PCR results for the 19 genes
tested confirmed the microarray data (Table 1). As expected
using HUVECs from different donors the magnitude of gene
expression changes by Q-PCR was not always similar but the
average fold induction or repression of genes by Dll4 was at
least 1.5 fold matching that of the microarray.
Dll4 target genes are regulated by immobilised Dll4
In order to confirm the regulation of genes by Dll4 signalling
by an alternative non-viral approach, HUVECs were cultured
on dishes coated with recombinant human Dll4 extracellular
domain (rDll4) or with BSA as a control. Immobilisation of the
Notch ligand is thought to mimic the tethering of the ligand on
the cell surface enabling Notch signalling which soluble ligands
usually fail to do as has been shown for Delta1 (Varnum-Finney
et al., 2000). This approach activated Notch signalling as
demonstrated by the accumulation of the cleaved active N1IC in
HUVECs cultured on rDll4 for 48 h (Fig. 2B).
Q-PCR validation of a subset of the candidate genes by this
method showed that all 12 genes tested were up-regulated and
all 5 were downregulated in HUVECs cultured on rDll4
compared to those cultured on BSA-coated dishes (Table 1).
This was in complete agreement with the cDNA microarray and
Q-PCR results from retroviral-infected HUVECs. In addition
this suggests that the regulation of these genes is via Notch
receptor cleavage rather than via Dll4-ICD as the recombinant
protein lacks the ICD.
Fig. 1. A heat map to show genes differentially regulated by Dll4 expression in
HUVECs. The heatmap and dendrogram show clustering of samples based on
the log2 expression ratio of 104 probesets. Clustering is based on manhattan
distance metric and single linkage. Heatmap colours represent log2 ratio of −5
(green) to 5 (red).
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Dll4 signalling regulates Hes1, Jagged1, MET, VEGFR1,
Snai2 and STAT1 proteins
In order to determine whether Dll4-induced mRNA changes
were reflected at the protein level we performed western blotting
for some of the confirmed targets and found that levels of Hes1
protein were higher in HUVECs expressing Dll4 by retroviral
infection and in HUVECs cultured on rDll4-coated plates
compared to control (Fig. 2A). Since the Q-PCR validation by
both approaches to induce Dll4 signalling yielded similar results
as did the western blotting for Hes1 (Fig. 2A) we then tested the
protein expression of STAT1, Jagged1, VEGFR1, snai2 and
MET in HUVECs cultured on rDll4-coated plates compared to
control. In HUVECs cultured on rDll4-coated plates, Notch
signalling was activated and this correlated with higher levels of
STAT1, Jagged1, Snai2 and full length VEGFR1 proteins and a
lower level of MET protein compared to control (Fig. 2B).
These protein expression changes correlated with the mRNA
level changes induced by Dll4.
In addition we used the γ-secretase inhibitor DAPT to
prevent Notch signalling and investigated its effect on Dll4-
induced regulation of elastin (the most upregulated gene by Q-
PCR), PCDH12 (the most down-regulated gene by Q-PCR) and
two other candidates. DAPT treatment inhibited the Dll4-
induced upregulation of elastin, sulfatase-1 and snai2 and
downregulation of PCDH12 at the mRNA level (Fig. 2C).
DAPT treatment inhibited Dll4 activation of Notch signalling as
demonstrated by the reduced accumulation of NICD in
HUVECs cultured on Dll4-coated plates in the presence of
DAPT (Fig. 2D). Furthermore DAPT treatment reduced the
protein expression changes of VEGFR1, VEGFR2, MET, snai2
and STAT1 induced in HUVECs cultured on rDll4-coated
plates (Fig. 2D).
Dll4-Notch signalling regulates the levels of soluble VEGFR1
Since Dll4 signalling upregulated the levels of full length
VEGFR1 protein in HUVEC, the effect of Dll4 signalling on the
levels of the inhibitory soluble alternative splice variant of
VEGFR1 (sVEGFR1) in the conditioned media of HUVEC
cultured on BSA or rDll4-coated plates was measured by
ELISA. The levels of sVEGFR1 were elevated in the
conditioned media of HUVEC cultured on Dll4-coated plates
compared to those cultured on BSA by 3.5 fold (Fig. 2E).
Treatment with DAPT inhibited the Dll4-induced elevation of
sVEGFR1 confirming that Notch signalling is necessary for
rDll4 to upregulate sVEGFR1.
ERK activation in response to VEGF165 and HGF is impaired
by Dll4 signalling
Since Dll4 signalling altered the gene expression of
several genes involved in VEGF signal transduction (Fig.
2; Table 1) we explored the effect of Dll4 signalling on the
ability of HUVECs to respond to VEGF165 stimulation. We
investigated the phosphorylation of ERK as ERK lies
downstream of VEGFR activation. HUVECs cultured on
Table 1
Genes involved in angiogenesis-related signalling pathways and biological pro-
cesses identified as Dll4 target genes by microarray analysis and Q-PCR validation
Genes (UniGene number) Microarray
(n=3)
Infection rDll4-coated
plates
Signalling pathways
VEGF
NRP1 (Hs.131704) −3.9 ND ND
NRP2 (Hs.471200) −2.7 −1.9 [0.2] (3) −1.6 [0.1] (3)
PlGF (Hs.252820) −6.9 −3.3 [0.6] (4) −2.8 [0.6] (4)
VEGFR1 (Hs.507621) 2.8 2.6 [0.4] (3) 3.9 [0.5] (3)
VEGFR2 (Hs.479756) −6.3 ND ND
FGF
FGF2 (Hs.284244) 7.3 ND ND
HGF
MET (Hs.132966) −1.9 −1.9 [0.3] (3) −2.3 [0.1] (3)
Notch
Notch 3 (Hs.8546) 7.0 9.7 [4.2] (5) 3.1 [0.2] (3)
Hey2§ (Hs.14427) 1.2 14.8 [6.0] (3) 12.9 [0.3] (3)
RASSF2 (Hs.379970) −6.8 −2.1 [0.4] (4) −2.2 [0.4] (3)
Jagged1 (Hs.224012) 3.2 1.5 [0.1] (5) 2.6 [0.3] (3)
Proliferation
Fibulin5 (Hs.332708) 3.0 5.8 [1.4] (3) 3.4 [0.3] (3)
Inhibin βA (Hs.28792) 5.6 5.0 [0.7] (5) 8.1 [0.9] (4)
STAT1 (Hs.470943) 4.3 1.8 [0.1] (5) ND
Migration and adhesion
CDH11 (Hs.116471) 3.9 2.3 [0.2] (5) ND
CXCR4 (Hs.421986) −10.4 ND ND
PCDH12 (Hs.439474) −1.9 −6.2 [1.3] (5) −7.0 [1.0] (5)
Snai2 (Hs.360174) 6.6 3.9 [0.5] (5) 4.9 [1.2] (4)
VCAM1 (Hs.109225) 12.5 15.0 [4.7] (4) 8.8 [2.3] (4)
Vessel guidance
RND1 (Hs.124940) 14.5 ND ND
Sema5A (Hs.321637) 28.9 22.6 [6.8] (3) 15.1 [3.9] (3)
Slit2 (Hs.558436) 3.4 ND ND
Slit3 (Hs.145601) 2.8 ND ND
Differentiation and morphogenesis
Elastin (Hs.252418) 30.1 143 [49] (5) 60.0 [33.6] (4)
EphrinB2 (Hs.149239) 4.2 ND ND
Integrin β3 (Hs.218040) −1.6 ND ND
Extracellular matrix-associated
Biglycan (Hs.821) 2.3 5.5 [1.3] (5) 6.7 [1.0] (4)
Collagen, typeIII, alpha1
(Hs.443625)
8.4 ND ND
Matrix metalloprotease
10 (Hs.2258)
9.8 ND ND
SDC1 (Hs.224607) 13.0 8.5 [2.2] (5) 6.0 [1.2] (4)
Sulfatase1 (Hs.409602) 5.4 23.3 [8.2] (5) 8.8 [4.1] (4)
Genes identified as Dll4 targets by cDNA microarray analysis categorized
according to the signaling pathway or biological process in which they play a role.
The average fold change in mRNA levels according to the microarray analysis is
shown. In addition the table shows a comparison between the average fold change
in mRNA levels of 20 genes identified by microarray analysis to be differentially
regulated by Dll4 signalling either in Dll4-expressing HUVECs compared to
empty vector control-infected HUVECs (infection) or HUVECs cultured on Dll4-
coated plates compared to HUVECs cultured on BSA-coated plates as a control
(rDll4-coated plates). The average fold change relative to expression in the
corresponding control cells is shown. ND, not determined. Parentheses, number
of independent experiments performed on HUVECs from separate donors. Square
brackets, S.E.M. All results are significant with pb0.05. §While Hey2 mRNAwas
not regulated by more than 1.5 fold in the microarray, Q-PCR results demonstrate
that it is upregulated by Dll4 signalling using both approaches.
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rDll4-coated plates for 48 h prior to starvation and
stimulation with 20 ng/mL VEGF165, had an impaired ability
to phosphorylate and therefore activate ERK (Fig. 3). In
addition, in a similar experiment, ERK activation in response
to 20 ng/mL HGF stimulation was also impaired demonstrat-
ing that the decreased level of MET protein following Dll4
stimulation reduced the ability of HUVEC to respond to HGF
(Fig. 3).
Dll4 effects on sprout length in a 3D-tubulogenesis assay
We investigated the effect of Dll4 expression in a 3D-
tubulogenesis assay that recapitulates crucial steps character-
istic of in vivo angiogenesis such as vessel elongation, vessel
branching and lumen formation (Nakatsu et al., 2003). In the
present study, expression of Dll4 clearly inhibited sprout
formation (Fig. 4A). Indeed, HUVECs infected with Dll4-
encoding retrovirus only formed short vessels (Fig. 4A) which
were about 50% of the length of mock or GFP-encoding empty
vector control-infected HUVECs (Fig. 4B). These experiments
demonstrated that increased Dll4-induced Notch signalling
attenuated tubulogenesis.
PlGF enhances tubulogenesis
In order to investigate whether modulation of VEGF sig-
nalling pathway components in the tubulogenesis assay may
contribute to the Dll4-induced phenotype described above, we
examined the effect of PlGF in this assay. As shown in Fig. 5A,
PlGF treatment led to enhanced tubulogenesis. PlGF is down-
regulated by Dll4 signalling, which has the opposite effect on
tubulogenesis in this assay (Fig. 4), suggesting that down-
regulation of PlGF by Dll4 may contribute to Dll4-induced
attenuation of tubulogenesis.
Dll4 signalling enhances PlGF-induced ERK activation
Since Dll4 signalling increased levels of the full-length
VEGFR1 receptor the ability of PlGF, the ligand for VEGFR1,
to activate ERK in HUVECs cultured on Dll4-coated plates
compared to BSA-coated plates was investigated. PlGF-
stimulated activation of ERK was enhanced in HUVEC cul-
tured on rDll4-coated plates and was also more prolonged
(Fig. 5B).
Discussion
Dll4, the most recently identified Notch ligand, is essential
for angiogenesis during embryonic vascular development.
Like VEGF, haploinsufficiency of Dll4 is embryonic lethal,
demonstrating its importance for successful angiogenesis
(Duarte et al., 2004; Gale et al., 2004; Krebs et al., 2004).
Recent reports have shown that blockade of Dll4 decreases
tumour growth but increases vessel density in contrast to the
previously accepted dogma that increased vessel density is
associated with increased tumour growth (Noguera-Troise
et al., 2006; Ridgway et al., 2006). However the underlying
mechanisms by which Dll4-mediated Notch signalling con-
tributes to the control of multiple signalling pathways to
coordinate such complex vascular processes remains unclear.
We have recently shown that Dll4 signalling increases tumour
growth and decreases vessel density but the resulting vessels
are larger and better perfused (Li et al., submitted). We
therefore suggest that Dll4 signalling may bring to an end the
initial proliferative phase of angiogenesis thus accounting for
the decreased vessel number and trigger a maturation phase to
refine and stabilise vessels to improve vascular function. This
idea is supported by recent in vivo data in Dll4+/− mice and
using pharmacological inhibitors of Dll4-Notch signalling
which demonstrate enhanced angiogenic sprouting and
increased vascular proliferation when Dll4 levels or signalling
is reduced in the retina or whole embryos (Hellstrom et al.,
2007; Lobov et al., 2007; Scehnet et al., 2007; Suchting et al.,
2007). However it is unclear how Dll4 regulates these
processes and investigating downstream mechanisms was the
purpose of this study. Here we identify Dll4-regulated genes
which may constitute the mechanism by which Dll4 signalling
coordinates such events.
The validity of using a microarray screen to identify Dll4
target genes is demonstrated by the fact that we have identified
previously known Notch target genes such as Hey1, and Hes1
(Iso et al., 2003b) consistent with other reports (Patel et al.,
2005; Williams et al., 2006).
Dll4 is highly expressed in tumour endothelium and is
induced by VEGF and hypoxia (Hainaud et al., 2006; Liu
et al., 2003; Mailhos et al., 2001; Patel et al., 2005). Dll4
signalling is known to decrease levels of VEGFR2 and the
VEGF co-receptor NRP1 (Williams et al., 2006) but here we
demonstrate that Dll4 signalling regulates several more
components of VEGF signalling including NRP2 and PlGF
(downregulated) and VEGFR1 (upregulated). These findings
support recent in vivo data where VEGFR2 expression was
elevated and VEGFR1 expression was decreased in the retina
of Dll4+/− mice compared to wild type controls (Suchting
et al., 2007).
By sequestration of VEGF away from VEGFR2 through
higher receptor–ligand affinity (Ferrara et al., 2003), VEGFR1
can act as a negative regulator of VEGF action by inhibiting
proliferation. Furthermore we have shown here that the
inhibitory soluble splice variant of VEGFR1, sVEGFR1, is
also upregulated in response to Dll4 contributing to the im-
pairment of VEGF signalling. PlGF can stimulate angiogen-
esis possibly by displacing VEGF from VEGFR1 (Ferrara et
al., 2003). Indeed we have shown enhanced tubulogenesis
induced by PlGF in the 3D tubulogenesis assay in agreement
with a previous report of PlGF-induced tubulogenesis using
primary microvascular endothelial cells (Cai et al., 2003).
Here we also show that the increased levels of full length
VEGFR1 receptor following Dll4 signalling can enhance ERK
activation in response to PlGF thereby indicating that the
down regulation of PlGF by Dll4 is an important part of the
programme of gene expression changes of VEGF pathway
components induced by Dll4 resulting in impaired VEGF
signalling. The inhibition of tubulogenesis by Dll4 in the 3D
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tubulogenesis assay (Fig. 4) is opposite to the effect of PlGF
in the same assay suggesting that downregulation of PlGF
contributes to this Dll4 phenotype.
Thus these data describe an efficient negative feedback loop
whereby Dll4 is induced by VEGF but then reduces the ability
of EC to respond to VEGF by regulating multiple components
of the VEGF pathway. We demonstrate that all these changes
result in impaired activation of ERK in response to VEGF165
stimulation in HUVEC cultured on Dll4-coated plates. That this
impairment of ERK signalling might contribute to the reduced
sprout length in the 3D-tubulogenesis assay is supported by the
observation that inhibition of ERK activation reduced tube
formation in a similar collagen gel tubulogenesis assay (Yang
et al., 2004).
The upregulation of sVEGFR1 by Dll4-Notch signalling is
particularly important as its levels could be monitored in serum
making it a potentially useful diagnostic tool to identify patients
who may benefit from anti-Dll4 therapy and to monitor their
response to such therapy. In addition, regulation of the expres-
sion of sVEGFR1 by Dll4 raises the possibility that rather than
only influencing angiogenesis via signalling to adjacent cells,
Dll4 may have an impact on angiogenesis over greater distances
by regulation of such soluble factors. Although exogenous
PIGF showed some enhancement of signalling associated with
full length VEGFR1 upregulation, this was not as extensive as
the upregulation of VEGFR1, and it is possible that secreted
sVEGFR1 limited this response, although fresh medium was
used to stimulate the cells.
Notch signalling is known to inhibit ECs proliferation
(Noseda et al., 2004; Sainson et al., 2005; Williams et al., 2006).
Results from the cDNA microarray indicate further mechanisms
by which Dll4 may limit EC proliferation for example by
upregulating the levels of fibulin5 and STAT1 which are known
to be involved in reducing EC proliferation (Albig et al., 2006;
Battle et al., 2006). A reduction in EC proliferation could
contribute to the reduced sprout length phenotype in the 3D
tubulogenesis assay and lead to the reduced vessel number in
Dll4-expressing tumours in vivo (Noguera-Troise et al., 2006;
Li et al., submitted).
Activation of the HGF receptor, MET, induces cell pro-
liferation, migration and tubulogenesis and branching morpho-
genesis and HGF regulates angiogenesis in vivo (Rosario and
Birchmeier, 2003). A constitutively active form of the Notch4
receptor has been shown to inhibit MET expression in MDA-
MB-435β4 cells (Stella et al., 2005) but here we demonstrate
that Dll4 signalling downregulated MET mRNA and protein.
Furthermore we showed that this Dll4-induced reduction of
MET protein impairs the ability of HUVEC to respond to HGF
stimulation and activate ERK. These results suggest that Dll4
signalling can negatively modulate key angiogenic pathways.
Dll4 is specifically expressed in arterial ECs (Benedito and
Duarte, 2005; Claxton and Fruttiger, 2004; Mailhos et al.,
2001) leading to the hypothesis that it is involved in the
differentiation of ECs as they mature and that tumour vas-
culature is arterial in nature. Our data showed that Dll4
signalling downregulated the venous-specific gene NRP2 and
upregulated genes associated with arterial vessels such as
ephrinB2 (Iso et al., 2006) and elastin which is necessary for
the elasticity of arterial vessels. Such a hypothesis is
Fig. 3. Activation of ERK by VEGF165 and HGF stimulation is impaired in
HUVECs cultured on rDll4-coated plates. HUVECs were cultured on Dll4-
coated plates for 48 h. 5 h prior to harvesting the cells were starved and then
left unstimulated or stimulated with the indicated growth factor (20 ng/mL) for
2 min or 10 min. Activation of ERK is indicated by detection of phosphory-
lated ERK p42/44 with a phospho-specific antibody and was attenuated in
HUVECs cultured on rDll4-coated plates. The blot was stripped and reprobed
with total ERK as a loading control. One experiment representative of two is
shown.
Fig. 2. Gene expression changes induced by Dll4 are reflected at the protein level and are inhibited by the γ-secretase inhibitor DAPT. (A) Protein extracts from
infected HUVECs or HUVECs cultured on BSA- or Dll4-coated plates for 48 h were separated by SDS-PAGE and immunoblotted. The levels of Hes1 protein
(30 kDa) were increased following Dll4 stimulation by both approaches. (B) Culture of HUVECs on Dll4-coated plates compared to BSA-coated plates for 48 h led to
an upregulation of STAT1 (84/91 kDa), Jagged1 (150 kDa), full length VEGFR1 (220 kDa), snai2 (30 kDa) and a downregulation of MET protein (145 kDa). (C)
Control empty vector retroviral infected cells (E.V.) or full length Dll4-retroviral infected HUVECs (F.L.D4) were cultured for 2 days in the presence of 2 μMDAPTor
the equivalent amount of DMSO as a control. DAPT prevented the Dll4-induced mRNA expression changes of elastin, Snai2, sulfatase-1 and PCDH12. One
experiment representative of three is shown. mRNA expression changes are represented as a fold change relative to expression in E.V. cells in DMSO. (D) HUVECs
were cultured on BSA or rDll4-coated plates for 48 h in the presence of 2 μMDAPTor the equivalent amount of DMSO. DAPT prevented the Dll4-induced changes in
protein levels of VEGFR1, VEGFR2, STAT1, MET and Snai2. Blots representative of three independent experiments are shown. (E) HUVECs were cultured on BSA
or rDll4-coated plates for 48 h in the presence of 2 μMDAPTor the equivalent amount of DMSO. HUVECs cultured on rDll4-coated plates for 48 h secreted 3.5-fold
more sVEGFR1 into the conditioned media than the control HUVEC per mg cellular protein and this was inhibited by DAPT treatment. Error bars represent standard
deviation. One experiment representative of two is shown.
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Fig. 5. PlGF enhances tubulogenesis and ERK activation in HUVECs cultured on rDll4-coated plates. (A) HUVECs placed in the 3D tubulogenesis assay were treated
2 days later with vehicle, 10 ng/mL or 50 ng/mL PlGF-supplemented media changing the media every other day for 5 treatments. PlGF treatment led to enhanced tube
formation. Scale bar, 100 μm. (B) HUVECs were cultured on BSA- or rDll4-coated plates for 48 h and starved for 5 h prior to stimulation with fresh starvation media
supplemented with 10 ng/mL PlGF for the indicated times. PlGF stimulation resulted in enhanced and prolonged ERK activation in HUVECs cultured on rDll4-coated
plates compared to control. One experiment representative of three is shown.
Fig. 4. Ectopic expression of Dll4 inhibits angiogenesis. Single donor HUVECs were infected by retrovirus to express GFP or full-length Dll4 and were compared to
mock infected cells for their ability to form tubes in an in vitro 3D-tubulogenesis assay. (A) Phase contrast images show a decrease in vessel length (at day 10)
following exogenous expression of Dll4. Scale bar represents 100 μm. (B) Quantification of vessel length in arbitrary units (a minimum of 100 sprouts was quantified).
Results from one experiment representative of three independent experiments are shown.
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reminiscent of but reciprocal to the role of the orphan nuclear
receptor, COUP-TFII, which suppresses Notch signalling and
arterial markers such as NRP1 to regulate venous cell fate (You
et al., 2005).
Only four genes from our microarray were also regulated by
Hey2 overexpression in HUVECs (Chi et al., 2003). The small
degree of concordance may reflect differences in array
technologies and relative degrees of expression of the constructs
but emphasises potential specificity as Dll4 regulates genes
independently of one downstream factor, Hey2.
In conclusion, in order to understand the molecular mecha-
nisms behind the effects of Dll4 on EC biology, elucidation of
the signal transduction pathways regulated specifically by Dll4
in ECs is essential. Here we report the use of a microarray
screen to systematically identify novel Dll4 targets. In accor-
dance with our in vitro 3D tubulogenesis assay and recent in
vivo data, we suggest that Dll4 limits EC proliferation and
angiogenesis and triggers the maturation and differentiation of
vessels possibly via the novel Dll4 targets identified herein.
Elucidation of the functions of these targets in angiogenesis is
the focus of our ongoing work.
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